Skip to main content
Erschienen in: Die Onkologie 11/2019

22.10.2019 | Peniskarzinom | CME

Peniskarzinom

Diagnose und Therapie

verfasst von: Prof. Dr. C. Protzel, O. W. Hakenberg

Erschienen in: Die Onkologie | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Aufgrund der Seltenheit des Peniskarzinoms in Mitteleuropa und Nordamerika stellen sich Betroffene oft erst in späten Tumorstadien vor. Die Diagnose kann meist als Blickdiagnose des Primärtumors gestellt werden. Klinisch sind dessen Morphologie, Größe und Lagebeziehungen sowie die inguinalen Lymphknoten von Interesse. Die Entfernung (mikro-)metastatisch befallener Lymphknoten ist prognostisch entscheidend. Diese sind weder klinisch noch bildgebend mit ausreichender Sicherheit diagnostizierbar, was ein invasives Lymphknotenstaging erforderlich macht. Das Peniskarzinom kann nur im lokalisierten und im Stadium der frühen regionären Lymphknotenmetastasierung durch Operation geheilt werden. Der Primarius ist inklusive der metastasenhaltigen Lymphknoten möglichst frühzeitig komplett zu entfernen. Der Wunsch nach Organerhalt muss unter konsequenter Beachtung von Sicherheitsabständen umgesetzt werden. Ein suffizientes Lymphknotenmanagement ist für das Langzeitüberleben entscheidend.
Literatur
1.
Zurück zum Zitat Protzel C, Ruppin S, Milerski S, Klebingat KJ, Hakenberg OW (2009) The current state of the art of chemotherapy of penile cancer: results of a nationwide survey of German clinics. Urologe A 48(12):1495–1498CrossRef Protzel C, Ruppin S, Milerski S, Klebingat KJ, Hakenberg OW (2009) The current state of the art of chemotherapy of penile cancer: results of a nationwide survey of German clinics. Urologe A 48(12):1495–1498CrossRef
2.
Zurück zum Zitat Sri D, Sujenthiran A, Lam W, Minter J et al (2018) A study into the association between local recurrence rates and surgical resection margins in organsparing surgery for penile squamous cell cancer. BJU Int 122(4):576–582CrossRef Sri D, Sujenthiran A, Lam W, Minter J et al (2018) A study into the association between local recurrence rates and surgical resection margins in organsparing surgery for penile squamous cell cancer. BJU Int 122(4):576–582CrossRef
3.
Zurück zum Zitat Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (Hrsg) (2002) Cancer incidence in five continents. IARC scientific publications no. 155. IARC, Lyon Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (Hrsg) (2002) Cancer incidence in five continents. IARC scientific publications no. 155. IARC, Lyon
4.
Zurück zum Zitat Dillner J, von Krogh G, Horenblas S, Meijer CJ (2000) Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl 205:189–193CrossRef Dillner J, von Krogh G, Horenblas S, Meijer CJ (2000) Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl 205:189–193CrossRef
5.
Zurück zum Zitat Madsen BS, van den Brule AJ, Jensen HL, Wohlfahrt J, Frisch M (2008) Risk factors for squamous cell carcinoma of the penis—population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 17:2683–2691CrossRef Madsen BS, van den Brule AJ, Jensen HL, Wohlfahrt J, Frisch M (2008) Risk factors for squamous cell carcinoma of the penis—population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 17:2683–2691CrossRef
6.
Zurück zum Zitat Favorito LA, Nardi AC, Ronalsa M, Zequi SC, Sampaio FJ, Glina S (2008) Epidemiologic study on penile cancer in Brazil. Int Braz J Urol 34:587–591 (discussion 591–583)CrossRef Favorito LA, Nardi AC, Ronalsa M, Zequi SC, Sampaio FJ, Glina S (2008) Epidemiologic study on penile cancer in Brazil. Int Braz J Urol 34:587–591 (discussion 591–583)CrossRef
7.
Zurück zum Zitat Harish K, Ravi R (1995) The role of tobacco in penile carcinoma. Br J Urol 75:375–377CrossRef Harish K, Ravi R (1995) The role of tobacco in penile carcinoma. Br J Urol 75:375–377CrossRef
8.
Zurück zum Zitat Rubin MA, Kleter B, Zhou M et al (2001) Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 159:1211–1218CrossRef Rubin MA, Kleter B, Zhou M et al (2001) Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 159:1211–1218CrossRef
9.
Zurück zum Zitat Cubilla AL, Dillner J, Schellhammer PF, Horenblas S, Ayala AG, Reuter VE, Von Krogh G (2004) Tumours of the penis. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA (Hrsg) World Health Organization Classification of tumours pathology and genetics of tumours of the urinary system and male genital organs. IARC Press, Lyon, S 280–290 Cubilla AL, Dillner J, Schellhammer PF, Horenblas S, Ayala AG, Reuter VE, Von Krogh G (2004) Tumours of the penis. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA (Hrsg) World Health Organization Classification of tumours pathology and genetics of tumours of the urinary system and male genital organs. IARC Press, Lyon, S 280–290
10.
Zurück zum Zitat Sobin LH, Gospodariwicz M, Wittekind C (Hrsg) (2009) TNM Classification of malignant tumours. UICC International Union Against Cancer, 7. Aufl. Wiley-Blackwell, New York Sobin LH, Gospodariwicz M, Wittekind C (Hrsg) (2009) TNM Classification of malignant tumours. UICC International Union Against Cancer, 7. Aufl. Wiley-Blackwell, New York
11.
Zurück zum Zitat Pizzocaro G, Nicolai N, Milani A (2009) Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol 55(3):546–551CrossRef Pizzocaro G, Nicolai N, Milani A (2009) Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol 55(3):546–551CrossRef
12.
Zurück zum Zitat Pagliaro LC, Williams DL, Daliani D et al (2010) Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 28(24):3851–3857CrossRef Pagliaro LC, Williams DL, Daliani D et al (2010) Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 28(24):3851–3857CrossRef
13.
Zurück zum Zitat Pizzocaro G, Piva L (1988) Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol 27:823–824CrossRef Pizzocaro G, Piva L (1988) Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol 27:823–824CrossRef
14.
Zurück zum Zitat Hakenberg OW, Nippgen JB, Froehner M, Zastrow S, Wirth MP (2006) Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU Int 98:1225–1227CrossRef Hakenberg OW, Nippgen JB, Froehner M, Zastrow S, Wirth MP (2006) Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU Int 98:1225–1227CrossRef
15.
Zurück zum Zitat Dexeus FH, Logothetis CJ, Sella A et al (1991) Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. J Urol 146:1284–1287CrossRef Dexeus FH, Logothetis CJ, Sella A et al (1991) Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. J Urol 146:1284–1287CrossRef
16.
Zurück zum Zitat Haas GP, Blumenstein BA, Gagliano RG et al (1999) Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol 161:1823–1825CrossRef Haas GP, Blumenstein BA, Gagliano RG et al (1999) Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol 161:1823–1825CrossRef
17.
Zurück zum Zitat Poetsch M, Schuart BJ, Schwesinger G, Kleist B, Protzel C (2007) Screening of microsatellite markers in penile cancer reveals differences between metastatic and nonmetastatic carcinomas. Mod Pathol 20:1069–1077CrossRef Poetsch M, Schuart BJ, Schwesinger G, Kleist B, Protzel C (2007) Screening of microsatellite markers in penile cancer reveals differences between metastatic and nonmetastatic carcinomas. Mod Pathol 20:1069–1077CrossRef
18.
Zurück zum Zitat Poetsch M, Hemmerich M, Kakies C et al (2011) Alterations in the tumor suppressor gene p16(INK4A) are associated with aggressive behavior of penile carcinomas. Virchows Arch 458(2):221–229CrossRef Poetsch M, Hemmerich M, Kakies C et al (2011) Alterations in the tumor suppressor gene p16(INK4A) are associated with aggressive behavior of penile carcinomas. Virchows Arch 458(2):221–229CrossRef
19.
Zurück zum Zitat Martins AC, Faria SM, Cologna AJ, Suaid HJ, Tucci S Jr. (2002) Immunoexpression of p53 protein and proliferating cell nuclear antigen in penile carcinoma. J Urol 167:89–92 (discussion 92–83)CrossRef Martins AC, Faria SM, Cologna AJ, Suaid HJ, Tucci S Jr. (2002) Immunoexpression of p53 protein and proliferating cell nuclear antigen in penile carcinoma. J Urol 167:89–92 (discussion 92–83)CrossRef
20.
Zurück zum Zitat Pizzocaro G, Algaba F, Horenblas S et al (2010) EAU penile cancer guidelines 2009. Eur Urol 57(6):1002–1012CrossRef Pizzocaro G, Algaba F, Horenblas S et al (2010) EAU penile cancer guidelines 2009. Eur Urol 57(6):1002–1012CrossRef
21.
Zurück zum Zitat Kayes O, Minhas S, Allen C, Hare C, Freeman A, Ralph D (2007) The role of magnetic resonance imaging in the local staging of penile cancer. Eur Urol 51:1313–1318 (discussion 1318–1319)CrossRef Kayes O, Minhas S, Allen C, Hare C, Freeman A, Ralph D (2007) The role of magnetic resonance imaging in the local staging of penile cancer. Eur Urol 51:1313–1318 (discussion 1318–1319)CrossRef
22.
Zurück zum Zitat Velazquez EF, Barreto JE, Rodriguez I, Piris A, Cubilla AL (2004) Limitations in the interpretation of biopsies in patients with penile squamous cell carcinoma. Int J Surg Pathol 12:139–146CrossRef Velazquez EF, Barreto JE, Rodriguez I, Piris A, Cubilla AL (2004) Limitations in the interpretation of biopsies in patients with penile squamous cell carcinoma. Int J Surg Pathol 12:139–146CrossRef
23.
Zurück zum Zitat Protzel C, Alcaraz A, Horenblas S, Pizzocaro G, Zlotta A, Hakenberg OW (2009) Lymphadenectomy in the surgical management of penile cancer. Eur Urol 55:1075–1088CrossRef Protzel C, Alcaraz A, Horenblas S, Pizzocaro G, Zlotta A, Hakenberg OW (2009) Lymphadenectomy in the surgical management of penile cancer. Eur Urol 55:1075–1088CrossRef
24.
Zurück zum Zitat Kroon BK, Horenblas S, Lont AP, Tanis PJ, Gallee MP, Nieweg OE (2005) Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol 173:816–819CrossRef Kroon BK, Horenblas S, Lont AP, Tanis PJ, Gallee MP, Nieweg OE (2005) Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol 173:816–819CrossRef
25.
Zurück zum Zitat Saisorn I, Lawrentschuk N, Leewansangtong S, Bolton DM (2006) Fine-needle aspiration cytology predicts inguinal lymph node metastasis without antibiotic pretreatment in penile carcinoma. BJU Int 97:1225–1228CrossRef Saisorn I, Lawrentschuk N, Leewansangtong S, Bolton DM (2006) Fine-needle aspiration cytology predicts inguinal lymph node metastasis without antibiotic pretreatment in penile carcinoma. BJU Int 97:1225–1228CrossRef
26.
Zurück zum Zitat Scher B, Seitz M, Reiser M et al (2005) 18F-FDG PET/CT for staging of penile cancer. J Nucl Med 46:1460–1465PubMed Scher B, Seitz M, Reiser M et al (2005) 18F-FDG PET/CT for staging of penile cancer. J Nucl Med 46:1460–1465PubMed
27.
Zurück zum Zitat Leijte JA, Kirrander P, Antonini N, Windahl T, Horenblas S (2008) Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol 54:161–168CrossRef Leijte JA, Kirrander P, Antonini N, Windahl T, Horenblas S (2008) Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol 54:161–168CrossRef
28.
Zurück zum Zitat Minhas S, Kayes O, Hegarty P, Kumar P, Freeman A, Ralph D (2005) What surgical resection margins are required to achieve oncological control in men with primary penile cancer? BJU Int 96:1040–1043CrossRef Minhas S, Kayes O, Hegarty P, Kumar P, Freeman A, Ralph D (2005) What surgical resection margins are required to achieve oncological control in men with primary penile cancer? BJU Int 96:1040–1043CrossRef
29.
Zurück zum Zitat Alnajjar HM, Lam W, Bolgeri M, Rees RW, Perry MJ, Watkin NA (2012) Treatment of carcinoma in situ of the glans penis with topical chemotherapy agents. Eur Urol 62(5):923–928CrossRef Alnajjar HM, Lam W, Bolgeri M, Rees RW, Perry MJ, Watkin NA (2012) Treatment of carcinoma in situ of the glans penis with topical chemotherapy agents. Eur Urol 62(5):923–928CrossRef
30.
Zurück zum Zitat Schlenker B, Gratzke C, Seitz M et al (2009) Fluorescence-guided laser therapy for penile carcinoma and precancerous lesions: long-term follow-up. Urol Oncol 29(6):788–793CrossRef Schlenker B, Gratzke C, Seitz M et al (2009) Fluorescence-guided laser therapy for penile carcinoma and precancerous lesions: long-term follow-up. Urol Oncol 29(6):788–793CrossRef
31.
Zurück zum Zitat Hegarty PK, Shabbir M, Hughes B et al (2009) Penile preserving surgery and surgical strategies to maximize penile form and function in penile cancer: recommendations from the United Kingdom experience. World J Urol 27:179–187CrossRef Hegarty PK, Shabbir M, Hughes B et al (2009) Penile preserving surgery and surgical strategies to maximize penile form and function in penile cancer: recommendations from the United Kingdom experience. World J Urol 27:179–187CrossRef
32.
Zurück zum Zitat de Crevoisier R, Slimane K, Sanfilippo N et al (2009) Long-term results of brachytherapy for carcinoma of the penis confined to the glans (N- or NX). Int J Radiat Oncol Biol Phys 74:1150–1156CrossRef de Crevoisier R, Slimane K, Sanfilippo N et al (2009) Long-term results of brachytherapy for carcinoma of the penis confined to the glans (N- or NX). Int J Radiat Oncol Biol Phys 74:1150–1156CrossRef
33.
Zurück zum Zitat Ficarra V, Galfano A (2007) Should the dynamic sentinel node biopsy (DSNB) be considered the gold standard in the evaluation of lymph node status in patients with penile carcinoma? Eur Urol 52:17–19 (discussion 20–11)CrossRef Ficarra V, Galfano A (2007) Should the dynamic sentinel node biopsy (DSNB) be considered the gold standard in the evaluation of lymph node status in patients with penile carcinoma? Eur Urol 52:17–19 (discussion 20–11)CrossRef
34.
Zurück zum Zitat Pizzocaro G, Piva L, Bandieramonte G, Tana S (1997) Up-to-date management of carcinoma of the penis. Eur Urol 32:5–15CrossRef Pizzocaro G, Piva L, Bandieramonte G, Tana S (1997) Up-to-date management of carcinoma of the penis. Eur Urol 32:5–15CrossRef
35.
Zurück zum Zitat Necchi A, Nicolai N, Colecchia M et al (2011) Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol 29(22):e650–e652CrossRef Necchi A, Nicolai N, Colecchia M et al (2011) Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol 29(22):e650–e652CrossRef
Metadaten
Titel
Peniskarzinom
Diagnose und Therapie
verfasst von
Prof. Dr. C. Protzel
O. W. Hakenberg
Publikationsdatum
22.10.2019
Verlag
Springer Medizin
Erschienen in
Die Onkologie / Ausgabe 11/2019
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-019-00662-z

Weitere Artikel der Ausgabe 11/2019

Die Onkologie 11/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.